Cargando…
A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss
BACKGROUND: Hirudin is a potent thrombin inhibitor but its antithrombotic properties are offset by bleeding side-effects. Because hirudin’s N-terminus must engage thrombin’s active site for effective inhibition, fusing a cleavable peptide at this site may improve hirudin’s risk/benefit ratio as a th...
Autores principales: | Sheffield, William P., Eltringham-Smith, Louise J., Bhakta, Varsha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887181/ https://www.ncbi.nlm.nih.gov/pubmed/29621998 http://dx.doi.org/10.1186/s12896-018-0431-4 |
Ejemplares similares
-
Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: Donkor, David A., et al.
Publicado: (2017) -
Addition of a sequence from α(2)-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
por: Sheffield, William P, et al.
Publicado: (2009) -
Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition
por: Roddick, Leigh Ann, et al.
Publicado: (2013) -
Incorporation of albumin fusion proteins into fibrin clots in vitro and in vivo: comparison of different fusion motifs recognized by factor XIIIa
por: Sheffield, William P, et al.
Publicado: (2011) -
Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant
por: Hamada, Mostafa, et al.
Publicado: (2021)